Do you want to read an article? Please log in or register.
Comparative efficacy of osimertinib with and without radiation therapy in EGFR-mutated nonsmall cell lung cancer with brain metastases
Lung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis
Lung Cancer
Pan Y, Gu Q
doi: 10.1016/j.lungcan.2025.108532
Lung, Respiratory and Thoracic Cancer
Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases
Lung Cancer
Huijs JWJ, Sadowska AM, Degens JHRJ, Steendam CMJ, Bensch F, Hijmering-Kappelle LBM, de Schrevel TMT, van Geffen WH, Youssef-El Soud M, Steens MMH, Pitz C, De Ruysscher DKM, Hendriks LEL
doi: 10.1016/j.lungcan.2025.108745
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME
doi: 10.1016/j.lungcan.2025.108551
Lung, Respiratory and Thoracic Cancer
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
Lung Cancer
Cho BC, Hayashi H, Lee JS, Lee SH, Danchaivijitr P, Cheng Y, Liu B, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yoshioka H, Nahit Şendur MA, Prabhash K, Azuma K, Lee YG, Lin CC, Matsumoto S, Sunpaweravong P, Xia Y, Martinez M, Bauml JM, Sethi S, Lu S
doi: 10.1016/j.lungcan.2025.108496
Lung, Respiratory and Thoracic Cancer
Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study
Lung Cancer
Uprety D, Abrahami D, Marcum ZA, Li B, Sang A, Davis M, Rifi N, Kelton JM, Ramaswamy K, Sanghvi P, Bazhenova L
doi: 10.1016/j.lungcan.2025.108436
Lung, Respiratory and Thoracic Cancer
CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression
Clin Lung Cancer
Wong WKY, Mok KKS, Tsui GPC, Chen OH, Loong HHF, Chan LL, Yan K, Mo F, Lee KWC, Lam KC, Mok FST, Johnson D, Chen ACC, Lam B, Lee M, Mok TSK, Li MSC
doi: 10.1016/j.cllc.2025.01.007
Lung, Respiratory and Thoracic Cancer
Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study
Transl Lung Cancer Res
Auclin E, Du Rusquec P, Albarran-Artahona V, Aboubakar F, Gerber H, Epaillard N, Recondo G, De Giglio A, Berthou H, Laguna JC, Gorria T, Blaquier JB, Jimenez-Munarriz B, Tagliamento M, Di Federico A, Sacco G, Minatta J, Girard N, Moran-Bueno T, Lopez-Castro R, Besse B, Mezquita L
doi: 10.21037/tlcr-24-881
Lung, Respiratory and Thoracic Cancer
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer
Lung Cancer
Sun F, Banwait MK, Singhal S, Herrmann A, Piotrowska Z, Yun K, Bazhenova L, Ullah AT, Guo EW, Wakelee HA, Neal JW, Das MS, Ramchandran KJ, Roy M, Diehn M, Myall NJ
doi: 10.1016/j.lungcan.2025.108747
Lung, Respiratory and Thoracic Cancer
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases
Lung Cancer
Frehner L, Schär S, Hayoz S, Petermichl V, Speicher P, I Rothschild S, Mauti LA, König D, Finazzi T, Froesch P, Marini S, Allemann A, Mark M, Janthur WD, Stamatiou A, Metaxas Y, Ermiş E, Wagner F, Früh M, Schmid S
doi: 10.1016/j.lungcan.2025.108813